The female hormone progesterone reduces coronavirus severity in men

Progesterone may ease severe COVID-19 in hospitalized men
Severe COVID-19 generally has better outcomes in hospitalized women than in men, leading to the idea that men hospitalized with COVID-19 might be treated with female hormones.
This concept showed "very encouraging" results in a single-center US pilot study that randomized (randomly selected) 42 men hospitalized with severe COVID-19. The findings were published in Chest: patients given progesterone injections for 5 days had significantly better outcomes than those receiving standard treatment.
Dr Sara Ghandehari, the study’s first author, who works at Cedars-Sinai Medical Center in Los Angeles, California, wrote, "The new findings suggest that administering 100 mg of progesterone twice daily by subcutaneous injection may offer a safe and effective approach to treating COVID-19 by improving clinical status in men with moderate to severe disease".
However, the authors caution that further studies are needed with larger, more diverse groups of participants, including postmenopausal women, and with participation from other hospitals.
How did the idea of giving men a female hormone arise?
Progesterone, a steroid hormone produced by the ovaries during reproductive cycles, naturally occurs only in premenopausal women. Its potential role in treating men with more severe COVID-19 (or postmenopausal women) comes from the observation that premenopausal (younger) women with COVID-19 have fewer hospital admissions, shorter hospital stays and less need for intubation support than postmenopausal women.
The authors suggest that higher progesterone levels may reduce the exaggerated response associated with severe COVID-19 through effects on the inflammatory immune response, with an immunomodulatory (regulatory) role.
In this study, progesterone doubled the recovery rate
The study’s primary endpoint was the change in clinical status from admission to day 7. Secondary endpoints were length of hospital stay, days of supplemental oxygen use and the need for intubation.
- The results showed that men receiving progesterone had a significant median improvement of 1.5 points in clinical status score 7 days after baseline compared with controls.
- During the first 7 days, fourteen men (70%) in the progesterone group improved, compared with seven men (32%) in the control group.
- In addition, during the first 7 days of the study, the probability of clinical improvement was 0.76 among 20 men receiving progesterone, compared with 0.55 among 22 placebo controls, a difference recorded as significant.
- The progesterone group also experienced a median reduction of 3 days in supplemental oxygen use and a median decrease of 2.5 days in hospital stay. The need for mechanical ventilation was also lower in the progesterone group than in the control group (0 versus 4 patients).
- No patient experienced a serious side effect attributable to progesterone, no side effects required discontinuation of progesterone, and treatment appeared to be well tolerated.
One patient in the progesterone group experienced two thromboembolic events (blood clots in a vessel), while two patients in the control group each experienced one such event. Patients in both groups reported comparable numbers of serious side effects, and one patient in each group died.
The study enrolled adult men hospitalized between April and August 2020 who tested positive for SARS-CoV-2, had evidence of lung involvement, had oxygen saturation of 94% or less on room air and were using supplemental oxygen. Patients were given medication for thromboembolism, a precaution recommended for all patients hospitalized with COVID-19. The authors note that there is no evidence that progesterone supplementation at the dosage currently used promotes thromboembolism.
The regimen required 100 mg progesterone injections twice daily for up to 5 days, but patients could stop treatment early if they recovered sufficiently to be discharged. The protocol also allowed other treatments with presumed benefit for COVID-19.
The enrolled patients had a mean age of 55; 78% were white and most were of Hispanic ethnicity. Overall, 85% were receiving supplemental oxygen on admission. Mean body mass index kg / 31.6 kg / m 2 was recorded. Of the patients, 48% had hypertension, 45% were obese and 25% had diabetes.
A 7-point assessment scale was used and scored according to these criteria: 1. Death; 2. Hospitalized with intubation and mechanical ventilation; 3. Hospitalized on high-flow oxygen devices; 4. Hospitalized requiring supplemental oxygen; 5. Hospitalized, not requiring supplemental oxygen; 6. Not hospitalized, with activity limitations; 7. Not hospitalized, with no activity limitations.
The study was investigator-initiated and received no commercial support. Ghandehari and another coauthor filed a patent application for the use of a progesterone agonist to treat COVID-19.
RELATED TOPICS
- COVID-19: current statistics for the world and Turkey
- Breaking news and scientific developments about coronavirus
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.